| Literature DB >> 35706859 |
Mehrnoosh Esmailiyan1, Mehdi Kargarfard1, Fahimeh Esfarjani1, Golnaz Vaseghi2.
Abstract
Background: Recently, the importance of chemokines and their receptors in carcinogenesis and the protective role of aerobic exercise in primary cancer development and progression is highlighted. Based on the facts that endurance exercise may result in hypoxia condition, and in addition, the effect of exercise therapy on the levels of CCL2, CCR2, and their related receptors in breast cancer (BC) model has not been investigated so far, therefore we aimed to evaluate the effect of eight-week noncontinuous aerobic training on the levels of CCL2, CCL5, and their related receptors; CCR2 and CCR5 in female BALB/C mice with BC.Entities:
Keywords: Breast cancer; CCL2; CCL5; CCR2; CCR5; chemokine; exercise
Year: 2022 PMID: 35706859 PMCID: PMC9188882 DOI: 10.4103/ijpvm.IJPVM_93_20
Source DB: PubMed Journal: Int J Prev Med ISSN: 2008-7802
The 8-week program of noncontinuous aerobic exercise
| Training period | Period (weeks) | Speed(m/min) | Time (min) | Repeat(days per week) | Activity |
|---|---|---|---|---|---|
| Introduction | 2 | 6-18 | 20 | 5 | Introduction to treadmill |
| Before- During cancer | 8 | 18 | 40 | 5 | The first 4-week period: aerobic exercise, the second 4-week period: Tumor formation and aerobic exercise, the third 4-week period: detraining |
| During-After cancer | 8 | 18 | 40 | 5 | The first 4-week period: detraining, the second 4-week period: |
| Tumor formation and aerobic exercise, the third 4-week period: aerobic exercise | |||||
| Before-After cancer | 8 | 18 | 40 | 5 | The first 4-week period: aerobic exercise, the second 4-week period: |
| Tumor formation and detraining, the third 4-week period: aerobic exercise |
Mean and standard deviation of investigated variables in the present study
| 1 | 2 | 3 | 4 | F | P | |
|---|---|---|---|---|---|---|
| TV (mm3) | 867.480±215.456a | 819.938±181.754b | 1069.740±424.103c | 1642.278±344.864 | 9.041 | 0.001 |
| CCL2 (pg.ml) | 7.79±2.11a | 6.17±1.19b | 4.74±1.12c | 15.40±3.29 | 30.12 | 0.001 |
| 4 | ||||||
| CCR2 fold of control | 0.6165±0.0635a | 0.5678±0.0703b | 0.2773±0.1608c | 1.00±0.00 | 60.74 | 0.001 |
| 9 | ||||||
| CCL5 (ng.ml) | 200.37±11.60a | 171.94±18.44b | 169.67±15.91c | 267.58±49.07 | 15.94 | 0.001 |
| 8 | ||||||
| CCR5 fold of control | 0.8710±0.2922 | 0.9889±0.2889 | 0.8597±0.1601 | 1.00±0.00 | 0.691 | 0.568 |
| ∆ W (g) | 4.31±0.6 | 4.1±0.4 | 3.83±0.5 | 5.28±0.5 |
Data are presented as Mean ± SD; TV, Tumor volume; CCL2, Chemokine (C-C motif) ligand 2; CCR2, C-C chemokine receptor type 2; CCL5, Chemokine (C-C motif) ligand 5; CCR5, C-C chemokine receptor type 5; ∆ Weight, Weight difference at the beginning of the study and at the end of the work ; 1 before-during, 2 before-after, 3during-after, 4control; a(P < 0.05) 1 vs 4; b(P < 0.05) 2 vs 4; c(P < 0.05) 3 vs 4 (there was no significant difference between the groups)
Figure 1CCL2 and CCL5 levels in the study groups; AA, BB, CC, P < 0.05
Figure 2CCR2 and CCR5 levels and TV in the study groups; AA, BB, CC, P < 0.05